Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

You may be eligible if

• DISEASE CHARACTERISTICS:
• Participants must have a diagnosis of a malignancy or clinical findings suggestive of a possible HIV-associated malignancy of one of three types:
• * Diffuse large B-cell lymphoma
• * Non-small cell lung malignancy
• The presence of any of the following conditions will exclude a participant from study enrollment:
• * Absence of sufficient diagnostic tumor-biopsy tissue material to meet the protocol requirements for baseline specimen submission (minimum specimen size of 10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the protocol specimen-collection requirements
• * Participants whose biopsies, for the purpose of this protocol, show a diagnosis of anal intraepithelial neoplasia or cervical intraepithelial neoplasia
• * Prior treatment for the study malignancy (including neo-adjuvants), since treatment can affect the mutational spectra of tumors
• HIV infection based on serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other Food and Drug Administration (FDA)-approved (licensed) HIV test; alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests
• PATIENT CHARACTERISTICS:
• Participants must be willing and able to sign an IRB-approved informed consent document
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics